Type I interferon signaling in B cells impairs humoral immunity during chronic viral infection by reducing clonal diversity and delaying germinal center entry, disrupting affinity maturation.
Type I interferon signaling in B cells plays a central role in compromising affinity maturation and vaccine efficacy during chronic viral infections.
Absolute Event Rate: 0% vs 0%
Affinity maturation and vaccine efficacy are compromised during chronic viral infections; however, underlying mechanisms remain unclear. Using the LCMV Cl13 model, we show that type I interferon (IFN-I) signaling in B cells plays a central role. IFN-I promotes early B cell activation but reduces clonal diversity and delays IgG1+ B cell entry into germinal centers (GCs), impairing high-affinity clone selection. Deletion of IFNAR1 in B cells partially restores nitrophenyl (NP)-specific IGHV1-72 and GC access but fails to rescue affinity maturation, suggesting a contribution of extrinsic factors. Somatic hypermutation is elevated in LCMV IFNAR1+/+ and IFNAR1-/- genotypes, though slightly less in IFNAR1-/- B cells. BASELINe analysis indicates weaker selection pressure in complementarity determining regions (CDRs), reflecting impaired affinity-based selection, correlating with a reduced follicular regulatory T cells/follicular helper T cells (TFR/TFH) ratio. Our results show that intrinsic and extrinsic IFN-I-dependent mechanisms synergize to disrupt B cell fate, establishing IFN-I as a key regulator of humoral immunity and highlighting mechanisms underlying poor vaccine response during persistent viral infection.
Laulhé et al. (Sat,) reported a other. Type I interferon signaling in B cells impairs humoral immunity during chronic viral infection by reducing clonal diversity and delaying germinal center entry, disrupting affinity maturation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: